drugset
drugset / Trial / NCT05609578

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

NCT05609578 ↗

Phase 2 Active not recruiting 90 enrolled Mirati Therapeutics Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

Timeline

Start
2022-11-22
Primary completion
2026-09-30
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Adagrasib Small molecule 400 mg Oral
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma